<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582305</url>
  </required_header>
  <id_info>
    <org_study_id>BLEO JET</org_study_id>
    <nct_id>NCT04582305</nct_id>
  </id_info>
  <brief_title>Bleomycin Jet Injections in Keloids</brief_title>
  <official_title>Intralesional Bleomycin Treatment of Keloids Using an Electronic Pneumatic Jet Injector: a Double-blind Randomized, Placebo-controlled Trial With Split-lesion Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Human Drug Research, Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, double-blind (patient and investigator), randomized,&#xD;
      placebo-controlled study with a split-lesion design, in which selected keloids will receive&#xD;
      three consecutive treatments of a) bleomycin and b) placebo (saline (NaCl 0,9%)),&#xD;
      administered with an electronic pneumatic jet injector.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, double-blind (patient and investigator), randomized,&#xD;
      placebo-controlled study with a split-lesion design.All study procedures will be performed at&#xD;
      the Department of Dermatology, Erasmus MC Medical Center in patients referred for scar&#xD;
      treatment to our outpatient clinic.&#xD;
&#xD;
      Clinical photos will be obtained after signing the informed consent form by patient and&#xD;
      investigator. Study visits and clinical assessments will be scheduled at baseline, 4 weeks, 8&#xD;
      weeks, and 12 weeks. Measurements include clinical photography, scar volume measured by&#xD;
      3D-camera, POSAS questionnaire, laser speckle contrast imaging to visualize keloid scar&#xD;
      vascularization, measurement of residue formation on the skin, and a treatment related&#xD;
      questionnaire. The keloid will be divided into two treatment areas, and randomly assigned to&#xD;
      three consecutive treatments of: a) bleomycin and b) placebo (saline (NaCl 0,9%)),&#xD;
      administered with an electronic pneumatic jet injector.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A single center, double-blind (patient and investigator), randomized, placebo-controlled study with a split-lesion design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume reduction</measure>
    <time_frame>12 weeks</time_frame>
    <description>Volume reduction of scar tissue in mm3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy using Patient and Observer Scar Assessment Scale (POSAS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluation of clinical efficacy using Patient and Observer Scar Assessment Scale (POSAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular perfusion</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluation of changes in keloid vascular perfusion using Laser Speckle Contrast Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residue formation on skin</measure>
    <time_frame>30 minutes</time_frame>
    <description>Evaluation of the average residue formation on skin in percentage of the injection volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related pain</measure>
    <time_frame>30 minutes</time_frame>
    <description>Evaluation of the procedure related pain using a numerical rating scale (NRS) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local skin reactions</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluation of the local skin reactions using self-taken photos in an e-diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluation of treatment satisfaction using a 5-point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability by evaluation of all adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluation of the tolerability by evaluating all adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Keloid</condition>
  <arm_group>
    <arm_group_label>Bleomycin jet-injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of bleomycin per treatment will be 2 mL, corresponding to 2 USP-E (units) of bleomycin. The maximum cumulative dosage of bleomycin will be 6 USP-E in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo jet-injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of normal saline per treatment will be 2 mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <description>Intralesional bleomycin treatment administered with an electronic pneumatic jet injector</description>
    <arm_group_label>Bleomycin jet-injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Intralesional placebo treatment of normal saline administered with an electronic pneumatic jet injector</description>
    <arm_group_label>Placebo jet-injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has provided written informed consent;&#xD;
&#xD;
          2. Subject is ≥ 18 years of age at time of screening;&#xD;
&#xD;
          3. Subject has at least one keloid scar of ≥ 4 cm in length, or two separate keloids with&#xD;
             a length of ≥2cm, with a minimum &gt; 1.0 cm apart in the same anatomical region.&#xD;
&#xD;
          4. Subject is willing to fill in questionnaires and take photos using an e-diary&#xD;
             application on their phone.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to any component of the test materials;&#xD;
&#xD;
          2. Pregnant or breast-feeding women (pregnancy test prior to treatment);&#xD;
&#xD;
          3. Previous bleomycin treatment of the keloid within the last 12 weeks prior to&#xD;
             screening.&#xD;
&#xD;
          4. Non-response to previous bleomycin treatments of the keloid.&#xD;
&#xD;
          5. Any medical or psychiatric condition which, in the investigator's opinion, would&#xD;
             preclude the participant from adhering to the protocol or completing the study per&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martijn van Doorn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liora Bik, MD</last_name>
    <phone>+ 31 107040110</phone>
    <email>l.bik@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martijn van Doorn, MD, PhD</last_name>
    <email>m.b.a.vandoorn@erasmusmc.nl</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>M.B.A. van Doorn</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Keloid</keyword>
  <keyword>Dermatology</keyword>
  <keyword>Bleomycin</keyword>
  <keyword>Jet-injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

